PML and acute promyelocytic leukemia: It has been reported that bortezomib, a proteasome inhibitor, impairs the ubiquitin–proteasome system that regulates protein homeostasis by inducing excessive PML-RARα accumulation, thereby increasing endoplasmic reticulum (ER) stress and killing APL cells [15].